Background: Drug desensitization allows for safe administration of a drug to a patient with a previous hypersensitivity reaction. Successful desensitization protocols have been described for different medications, including protocols for oncology patients. Few cases of desensitization to sorafenib and imatinib have been described in the literature so far.
Objective: The objective of this paper is to describe the process of the sorafenib and imatinib drug hypersensitivity diagnosis and desensitization process in two patients.
Methods: Two oncology patients who experienced non-immediate hypersensitivity reactions to sorafenib and imatinib underwent desensitization to these drugs. We designed a protocol for the first patient and used a modified protocol from the literature for the second patient.
Results: By using a slow desensitization technique and gradual tapering of corticosteroids and antihistamines, both patients reached the target dose of the incriminated drug.
Conclusions: Desensitization to sorafenib and imatinib can be an effective therapeutic option in patients with hypersensitivity to those medications, without alternative treatment options.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10969993 | PMC |
| http://dx.doi.org/10.3390/healthcare12060601 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension-A Systematic Review.
Int J Mol Sci
November 2024
Department of Biopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151 Lodz, Poland.
Treatment options for pulmonary arterial hypertension (PAH) have improved substantially in the last 30 years, but there is still a need for novel molecules that can regulate the excessive accumulation of pulmonary artery smooth muscle cells (PASMCs) and consequent vascular remodeling. One set of possible candidates are protein kinases. The study provides an overview of existing preclinical and clinical data regarding small-molecule protein kinase inhibitors in PAH.
View Article and Find Full Text PDFComprehensive analysis of bioinformatics and system biology reveals the association between Girdin and hepatocellular carcinoma.
PLoS One
December 2024
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.
Introduction: Hepatocellular carcinoma is one of the leading causes of cancer-related mortality worldwide. The actin-binding protein Girdin is overexpressed in various tumors, promoting tumorigenesis and progression. However, the exact mechanisms by which Girdin regulates liver cancer remain poorly understood.
View Article and Find Full Text PDFA real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India.
Front Oncol
October 2024
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Background: The medical management of DT comprises tyrosine kinase inhibitors (TKIs), hormonal agents, anti-inflammatory drugs with the recently approved gamma secretase inhibitor nirogacestat being the current standard of care. Real-world data on evolving treatment landscapes of DT remains scarce.
Methods: This is a retrospective study of patients with DT registered between 1995 and 2020 at All India Institute of Medical Sciences, New Delhi and Tata Medical Center, Kolkata.
Gene-expression profile analysis to disclose diagnostics and therapeutics biomarkers for thyroid carcinoma.
Comput Biol Chem
December 2024
Bioinformatics Lab (Dry), Department of Statistics, University of Rajshahi, Rajshahi 6205, Bangladesh. Electronic address:
Article Synopsis
- Thyroid carcinoma (THCA) is the most common endocrine cancer in the head and neck, with ongoing research investigating its genetic links and molecular mechanisms, which are still not fully understood.
- While drug therapies are the main treatment for advanced THCA, many patients develop resistance over time, highlighting the need for multi-targeted drug therapies.
- A study identified 80 differentially expressed genes related to THCA and pinpointed eight key genes (some upregulated, some downregulated) that could serve as potential biomarkers for diagnosis and prognosis.
Sorafenib induces cachexia by impeding transcriptional signaling of the SET1/MLL complex on muscle-specific genes.
iScience
October 2024
Institute of Molecular and Cell Physiology, Hannover Medical School, Hannover, Germany.
Article Synopsis
- Chemotherapeutics often cause muscle wasting, known as cachexia, which is crucial to understand for improving cancer treatments.
- This study focused on Sorafenib, a tyrosine kinase inhibitor, revealing that it disrupts muscle cell function by altering gene transcription and reducing an important epigenetic marker.
- Unique to Sorafenib, this disruption affected muscle cell assembly and function, while other TKIs like Nilotinib and Imatinib did not have the same impact, suggesting new strategies for reducing chemotherapy-induced cachexia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!